Product image of Heparīna Nātrijs Panpharma (Heparin Sodium) supplied by GNH India

Heparīna Nātrijs Panpharma

Active Ingredient:
Heparin Sodium
Origin:
EU

Heparīna Nātrijs Panpharma (Heparin Sodium)

Heparīna Nātrijs Panpharma is a prescription anticoagulant that contains the active ingredient heparin sodium. It is supplied in an injectable form for intravenous administration and conforms to EU pharmaceutical standards. The product is used to inhibit clot formation by enhancing antithrombin III activity, providing therapeutic anticoagulation in various clinical settings.

Manufacturer / TM Owner

Panpharma

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Heparīna Nātrijs Panpharma is indicated for several antithrombotic purposes in hospital and procedural environments.

  • Prevention and treatment of venous thromboembolism (VTE)
  • Prophylaxis of deep vein thrombosis (DVT) in patients undergoing surgery
  • Management of acute coronary syndromes, including unstable angina
  • Prevention of clot formation in extracorporeal circuits such as dialysis or cardiopulmonary bypass
  • Adjunct therapy during percutaneous coronary interventions (PCI)

Side Effects

Adverse reactions to Heparīna Nātrijs Panpharma can vary in frequency and severity.

Common

  • Minor bleeding at injection site
  • Hematuria (blood in urine)
  • Epistaxis (nosebleed)
  • Gastrointestinal discomfort
  • Elevated liver enzymes

Serious

  • Heparin-induced thrombocytopenia (HIT)
  • Major hemorrhage (intracranial, gastrointestinal)
  • Allergic reactions including anaphylaxis
  • Spontaneous bleeding into joints or muscles

Precautions & Warnings

When prescribing Heparīna Nātrijs Panpharma, clinicians should consider several safety factors.

  • Assess baseline coagulation status and platelet count before initiation
  • Monitor activated partial thromboplastin time (aPTT) or anti‑Xa levels during therapy
  • Use caution in patients with a history of heparin-induced thrombocytopenia
  • Adjust dose in renal or hepatic impairment as needed
  • Avoid use in active major bleeding or uncontrolled hypertension
  • Counsel patients on signs of bleeding and when to seek medical attention

Avoid Interactions

Heparīna Nātrijs Panpharma may interact with other agents that affect hemostasis.

Avoid

  • Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without close monitoring
  • Thrombolytic agents such as alteplase or streptokinase
  • High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk

Use with caution

  • Antiplatelet drugs (e.g., clopidogrel, ticagrelor)
  • Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents
  • Glycoprotein IIb/IIIa inhibitors used during cardiac procedures

Frequently Asked Questions

Heparīna Nātrijs Panpharma contains heparin sodium, which binds to antithrombin III and accelerates its inhibition of thrombin (factor IIa) and factor Xa, thereby reducing clot formation.

It is commonly used for preventing and treating venous thromboembolism, prophylaxis of deep vein thrombosis in surgical patients, management of acute coronary syndromes, and preventing clotting in extracorporeal circuits such as dialysis.

The product is supplied as an injectable solution for intravenous (IV) administration under the supervision of a healthcare professional.

Routine monitoring of activated partial thromboplastin time (aPTT) or anti‑Xa activity is recommended to maintain therapeutic anticoagulation and reduce bleeding risk.

Dose adjustments or careful monitoring may be needed in patients with significant renal or hepatic dysfunction, as drug clearance can be affected.

Signs of HIT include a sudden drop in platelet count, new thrombosis, skin lesions at injection sites, and systemic symptoms such as fever or chills.

Aspirin can increase bleeding risk; concurrent use should be evaluated by a clinician and patients should be monitored closely.

Patients should seek immediate medical attention, inform the healthcare provider about the bleeding, and may need laboratory evaluation of coagulation parameters.

Contraindications include active major bleeding, known hypersensitivity to heparin or pork products, and a history of heparin‑induced thrombocytopenia.

Heparīna Nātrijs Panpharma is an unfractionated heparin with a broader range of molecular weights, requiring aPTA monitoring, whereas low‑molecular‑weight heparins have more predictable pharmacokinetics and often do not require routine lab monitoring.

The pregnancy safety category is not specified; clinicians must weigh potential benefits against risks and follow local guidelines when considering use in pregnant patients.

The product should be stored at controlled room temperature, protected from light, and kept in the original packaging until use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Heparin Sodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT